Comparison
GHRP-6 vs. Selank
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Growth
Research other
CAS no.
87616-84-0
129954-34-3
Molecular weight
873.02 g/mol
751.85 g/mol
Half-life
0.4 h
0.3 h
Sequence
His-D-Trp-Ala-Trp-D-Phe-Lys-NH2Thr-Lys-Pro-Arg-Pro-Gly-ProMechanism of action
GHRP-6
GHRP-6 is a high-affinity agonist of the growth-hormone secretagogue receptor 1a (GHSR-1a) — the same receptor later shown to bind the endogenous hormone ghrelin. The identification of GHRP-6 as a pharmacological anchor led to cloning of GHSR in 1996 and the discovery of ghrelin itself in 1999. GHRP-6 stimulates pituitary GH secretion via a pathway independent of GHRH and can be combined synergistically with GHRH. Via GHSR in the hypothalamus it additionally activates NPY/AgRP neurons, producing an orexigenic (appetite-stimulating) effect in animal models.
Selank
Selank is a glyproline-tuftsin analog. Proposed mechanisms include modulation of the GABAergic system, effects on serotonin bioavailability, and influence on enkephalinases. Animal studies show anxiolytic and neuroprotective markers; a clear receptor target is not established.
Evidence base
Highest evidence
Human trial
Human trial
Studies
4
4
of which in humans
2
2
Effects recorded
4
3
Open conflicts
1
0
Documented adverse events
2
1